SUBSEQUENT EVENTS (Tables)

6 Months Ended

Jun. 30, 2018

Subsequent Events [Abstract]

Condensed Balance Sheet [Table Text Block]

The Company is evaluating the proper accounting treatment for the classification of the Series E Warrants and the allocation of proceeds between common stock, the Series C Preferred Stock, and Additional paid-in capital. All proceeds are included in common stock and additional paid in capital on a pro forma basis.

CELLECTAR BIOSCIENCES, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

	As Reported June 30, 2018 (Unaudited)			Pro Forma June 30, 2018 (Unaudited)
ASSETS
CURRENT ASSETS:
Cash and cash equivalents	$	4,180,744		$	19,068,667
Restricted cash		55,000			55,000
Prepaid expenses and other current assets		780,559			780,559
Total current assets		5,016,303			19,904,226
FIXED ASSETS, NET		211,970			211,970
GOODWILL		1,675,462			1,675,462
OTHER ASSETS		93,086			93,086
TOTAL ASSETS	$	6,996,821		$	21,884,744
LIABILITIES AND STOCKHOLDERS’ EQUITY
CURRENT LIABILITIES:
Accounts payable and accrued liabilities		2,093,646			2,093,646
Derivative liability		152,000			152,000
Capital lease obligations, current portion		3,203			3,203
Deferred rent		40,438			40,438
Total current liabilities		2,289,287			2,289,287
LONG-TERM LIABILITIES:
Capital lease obligation, less current portion		568			568
Total long-term liabilities		568			568
TOTAL LIABILITIES		2,289,855			2,289,855
COMMITMENTS AND CONTINGENCIES (Note 8)
STOCKHOLDERS’ EQUITY:
Preferred stock, $0.00001 par value; 7,000 shares Series C authorized; none actual; 1,114 pro forma		—			—
Common stock, $0.00001 par value; 80,000,000 shares authorized; 1,774,992 actual; 3,129,992 pro forma		17			31
Additional paid-in capital		95,452,779			110,340,688
Accumulated deficit		(90,745,830	)		(90,745,830	)
Total stockholders’ equity		4,706,966			19,594,889
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$	6,996,821		$	21,884,744